TUmeurs THYroïdiennes REFractaires.
Liste des publications TUTHYREF
  • Atallah V, Hocquelet A, Do Cao C, Zerdoud S, De La Fouchardiere C, Bardet S, et al.: Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients. Thyroid Off J Am Thyroid Assoc 2016 Aug;26:1085–1092.

  • Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, et al.: Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J Clin Oncol Off J Am Soc Clin Oncol 2015 Sep 10;33:2885–2892.

  • Chougnet CN, Schlumberger M, Leboulleux S, Baudin E: [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas]. Bull Cancer (Paris) 2014 Sep;101:891–895.

  • Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, et al.: Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid Off J Am Thyroid Assoc 2015 Apr;25:386–391.

  • Crouzeix G, Michels J-J, Sevin E, Aide N, Vaur D, Bardet S, et al.: Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 2012 Sep;97:3046–3050.

  • de la Fouchardière C: Targeted treatments of radio-iodine refractory differentiated thyroid cancer. Ann Endocrinol 2015 Feb;76:1S34-39.

  • Massicotte M-H, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet A-L, et al.: Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 2014 Apr;170:575–582.

  • Schlumberger M, French TUTHYREF Network: Targeted therapy in refractory thyroid cancer. Eur J Cancer Oxf Engl 1990 2011 Sep;47 Suppl 3:S328-329.

  • Schlumberger M, Leboulleux S: Treatment of distant metastases from follicular cell-derived thyroid cancer. F1000prime Rep 2015;7:22.

  • Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al.: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012 May 3;366:1663–1673.

  • Tisset H, Kamar N, Faugeron I, Roy P, Pouteil-Noble C, Klein M, et al.: Is thyroid cancer recurrence risk increased after transplantation? J Clin Endocrinol Metab 2013 Oct;98:3981–3988.


En visitant notre site Web, vous acceptez que nous utilisions des cookies pour vous assurer d'obtenir la meilleure expérience.